Antiemetic effect of palonosetron and first-generation serotonin inhibitors in combination with aprepitant and dexamethasone
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yun, Jina | - |
dc.contributor.author | Kim, Han Jo | - |
dc.contributor.author | Lim, Sung Hee | - |
dc.contributor.author | Kim, Se Hyung | - |
dc.contributor.author | Kim, Chan Kyu | - |
dc.contributor.author | Park, Seong Kyu | - |
dc.date.accessioned | 2022-11-29T05:42:35Z | - |
dc.date.available | 2022-11-29T05:42:35Z | - |
dc.date.issued | 2022-08 | - |
dc.identifier.issn | 1940-5901 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/21821 | - |
dc.description.abstract | Background/Aims: Palonosetron has shown to be more effective than serotonin inhibitors, like ondansetron and dolasetron, in preventing chemotherapy-induced nausea and vomiting (CINV) among patients undergo-ing moderately emetogenic chemotherapy (MEC), while being similarly effective as ondansetron among patients undergoing highly emetogenic chemotherapy (HEC). The present study aimed to examine the antiemetic effective-ness of palonosetron and other serotonin inhibitors in combination with aprepitant and dexamethasone for MEC or HEC. Methods: A retrospective analysis was performed with the data from patients who were treated with serotonin inhibitors, aprepitant, and dexamethasone for MEC or HEC between July 2009 and January 2011. Patients in Group A were treated with palonosetron, aprepitant, and dexamethasone. Patients in Group B were treated with first-generation serotonin inhibitors, aprepitant, and dexamethasone. Results: Final data for analysis included 370 patients (i.e., 223 and 117 patients respectively in Groups A and B). The numbers of patients who received MEC and HEC were respectively 110 and 260. No case of grade 3-4 nausea/vomiting was detected. There were no significant differences between the Groups A and B across the acute and delayed CINV phases. The proportions of emesis-free patients during the acute phase (0-24 h) in both groups were similar: 78% and 76% respectively in Groups A and B (P=0.57). The proportions of emesis-free patients during the delayed phase (24-120 h) in both groups were similiar: 67% and 71% respectively (P=0.48). Conclusions: When combined with aprepitant and dexamethasone, all serotonin inhibitors seem to be equally effective for MEC orr HEC. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | e-Century Publishing Corporation | - |
dc.title | Antiemetic effect of palonosetron and first-generation serotonin inhibitors in combination with aprepitant and dexamethasone | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.wosid | 000837158600003 | - |
dc.identifier.bibliographicCitation | International Journal of Clinical and Experimental Medicine, v.15, no.7, pp 223 - 230 | - |
dc.citation.title | International Journal of Clinical and Experimental Medicine | - |
dc.citation.volume | 15 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 223 | - |
dc.citation.endPage | 230 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | esci | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | CHEMOTHERAPY-INDUCED NAUSEA | - |
dc.subject.keywordPlus | MODERATELY EMETOGENIC CHEMOTHERAPY | - |
dc.subject.keywordPlus | PLACEBO-CONTROLLED TRIAL | - |
dc.subject.keywordPlus | HIGH-DOSE CISPLATIN | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.subject.keywordPlus | ANTAGONIST APREPITANT | - |
dc.subject.keywordPlus | NEUROKININ-1 ANTAGONIST | - |
dc.subject.keywordPlus | RECEPTOR ANTAGONIST | - |
dc.subject.keywordPlus | 5HT(3) ANTAGONIST | - |
dc.subject.keywordAuthor | Chemotherapy-induced nausea and vomiting | - |
dc.subject.keywordAuthor | serotonin antagonist | - |
dc.subject.keywordAuthor | aprepitant | - |
dc.subject.keywordAuthor | highly emetogenic chemotherapy | - |
dc.subject.keywordAuthor | moderately emetogenic chemotherapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.